Rising chronic disease rates and technological advancements in immunoassays are expected to drive a 7.6% annual growth rate through 2030.

The global in vitro diagnostics (IVD) market is projected to reach USD 157.63 billion by 2030, according to a report from MarketsandMarkets. The market, which was valued at USD 101.05 billion in 2024, grew to USD 109.06 billion in 2025 and is expected to maintain a compound annual growth rate of 7.6% through the end of the decade.

This expansion is driven by an increasing global burden of chronic and infectious diseases, alongside a rising clinical demand for early and high-precision detection. While emerging economies are seeing growth through government-backed screening programs, the industry faces challenges from stringent regulatory frameworks, including European IVDR requirements and Food and Drug Administration standards, which can increase compliance costs and development timelines.

Immunoassays and Reagents Lead Market Segments

Investment in the IVD sector is currently concentrated in segments that support workflow efficiency and recurring revenue, according to the report. Reagents and kits hold the largest share of the market, serving as the essential components for automated analyzers and clinical chemistry workflows.

Technologically, immunoassays lead the sector. This growth is supported by high-sensitivity chemiluminescence and multiplexing platforms that provide rapid turnaround times for oncology, endocrinology, and infectious disease testing. Blood, serum, and plasma remain the dominant clinical specimens used in diagnostic workflows across hospital networks and centralized laboratories.

Geographically, North America maintains the largest market share due to its established healthcare infrastructure and investments in precision medicine, though emerging markets are narrowing the gap.

Addressing Personnel Shortages with Automation

Despite the positive market outlook, laboratory directors and chief operating officers face significant operational friction, according to the report. The industry continues to struggle with shortages of skilled laboratory personnel, supply chain volatility, and high costs associated with instrument maintenance.

To mitigate these risks, many healthcare institutions are increasing their reliance on fully automated, high-throughput systems. These platforms are designed to reduce manual intervention, stabilize testing environments, and standardize clinical decision-making across the laboratory.

The competitive landscape is characterized by consolidation among top market players, including Roche, Abbott, Danaher, Siemens Healthineers, and Thermo Fisher Scientific. Other companies contributing to the market ecosystem include Sysmex Corporation, Bio-Rad Laboratories, Becton, Dickinson and Company, and Agilent Technologies.

ID 286643215 © Rimidolove | Dreamstime.com

Related Reading: